Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency
Haemophilia · 2024
DOI: 10.1111/hae.14894 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Haemophilia, 2024. Verfasst von Miguel A Escobar und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Health Science Center at Houston-McGovern Medical School and the Gulf States Hemophilia and Thrombophilia Center, Houston, Texas,…. Hauptthemen laut MEDLINE: Factor X, Factor X Deficiency. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bio Products Laboratory (Elstree, United Kingdom).
Abstract (Originalsprache)
Introduction
Hereditary factor X (FX) deficiency (HFXD) is an autosomal recessive rare bleeding disorder that leads to defects in the FX protein. Depending on the degree of deficiency, patients may be at risk of life‐threatening bleeding episodes. Historical treatments for FX deficiency include prothrombin complex concentrates, which can increase the risk of thrombosis, and fresh frozen plasma, which can cause volume overload and transfusion reactions. Plasma‐derived FX (pdFX), a single‐factor, high‐purity, high‐potency human FX treatment, was approved in 2015 in the United States and in 2016 in Europe for on‐demand treatment and prophylaxis of bleeding episodes and perioperative management of patients with HFXD.
Methods
Five studies that examined the use of pdFX in patients with mild (plasma FX activity [FX:C] ≥5 IU/dL), moderate (FX:C ≥1 and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Texas Health Science Center at Houston-McGovern Medical School and the Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, USA.
- Department of Pediatrics, Division of Hemato-Oncology, Ege University Faculty of Medicine, İzmir, Turkey.
ORCID-Profile: Miguel A Escobar, Kaan Kavakli
Förderung
- Bio Products Laboratory (Elstree, United Kingdom)
Zitieren
APA
Escobar, M. A., & Kavakli, K. (2024). Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency. Haemophilia. https://doi.org/10.1111/hae.14894
Vancouver
Escobar MA, Kavakli K. Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency. Haemophilia. 2024. doi:10.1111/hae.14894
BibTeX
@article{Escobar2024,
author = {Escobar, Miguel A and Kavakli, Kaan},
title = {Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.14894}
}
EUVIMED